Compass Therapeutics vs Inhibrx Biosciences
CMPX and INBX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CMPX and INBX compare
Inhibrx Biosciences is the larger company, worth 8.9 times as much as Compass Therapeutics ($1.3B against $150M).
Compass Therapeutics scores higher on the StockData Score (7 against 1 for Inhibrx Biosciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CMPX | INBX |
|---|---|---|
| Size and price | ||
| Market cap | $150M | $1.3B |
| Share price | $0.830 | $90.59 |
| Change, 1 year | −80.6% | 14.7% |
| Change, 5 years | −76.1% | 109% |
| Beta (5Y) | 1.27 | 1.72 |
| Employees | 39 | 110 |
| StockData Score | ||
| Total score | 7 (better) | 1 |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 1.0× | – |
| FCF yield | −41.4% | −9.9% (better) |
| Growth | ||
| Revenue growth, 5Y average | – | −36.8% |
| Profitability | ||
| Return on equity | −49.0% (better) | −1774% |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −8.2× |
| Current ratio | 6.79 (better) | 5.07 |
| Altman Z-score | −2.02 | −0.86 (better) |
| Piotroski F-score | 3 (better) | 1 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 92.0% | 97.4% |
| Held by insiders | 26.3% | 35.4% |
| Insider net buying, 12 months | $96.8K | $6.1M (better) |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 30.7% | 35.7% |
Go deeper
- CMPX stock overview
- CMPX income statement
- CMPX valuation and score
- INBX stock overview
- INBX income statement
- INBX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.